pyrimidin-2-one beta-ribofuranoside and Intestinal Neoplasms

pyrimidin-2-one beta-ribofuranoside has been researched along with Intestinal Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Byun, HM; Chuang, JC; Dubeau, L; Egger, G; Jones, PA; Laird, PW; Long, T; Marquez, VE; Yang, AS; Yoo, CB	1

Other Studies

1 other study(ies) available for pyrimidin-2-one beta-ribofuranoside and Intestinal Neoplasms

Article	Year
Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer prevention research (Philadelphia, Pa.), 2008, Volume: 1, Issue:4 Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Carcinoma; Cytidine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Profiling; Genes, APC; Intestinal Mucosa; Intestinal Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Oligonucleotide Array Sequence Analysis; Organ Specificity; Sex Characteristics; Time Factors	2008

Article

Year

Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice.

Cancer prevention research (Philadelphia, Pa.), 2008, Volume: 1, Issue:4

Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Carcinoma; Cytidine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Profiling; Genes, APC; Intestinal Mucosa; Intestinal Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Oligonucleotide Array Sequence Analysis; Organ Specificity; Sex Characteristics; Time Factors

2008